60 Degrees Pharmaceuticals, Inc. (SXTP)

NASDAQ: SXTP · Real-Time Price · USD

1.840

+0.020 (1.10%)

At close: Mar 28, 2025, 4:00 PM

1.823

-0.017 (-0.91%)

After-hours: Mar 28, 2025, 7:55 PM EDT

SXTP Employees

60 Degrees Pharmaceuticals had 3 employees as of December 31, 2023. The number of employees increased by 1 or 50.00% compared to the previous year.

Employees

3

Change (1Y)

1

Growth (1Y)

50.00%

Revenue / Employee

$227,115

Profits / Employee

-$2,649,036

Market Cap

2.71M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

SXTP News

5 weeks ago - 60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
5 weeks ago - 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - GlobeNewsWire
6 weeks ago - Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF® - GlobeNewsWire
7 weeks ago - 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
7 weeks ago - 60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
2 months ago - 60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
2 months ago - 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewsWire
2 months ago - 60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis - GlobeNewsWire